Regencell Bioscience Holdings (RGC) Other Accumulated Expenses (2025)
Regencell Bioscience Holdings' (RGC) quarterly Other Accumulated Expenses came in at $8873.0 in Q4 2025, up 89.84% on a QoQ basis from $4674.0 in Q2 2025.
Regencell Bioscience Holdings (RGC) Other Accumulated Expenses (2025) Analysis & Trends
Regencell Bioscience Holdings (RGC) has 1 years of Other Accumulated Expenses data on file, last reported at $8873.0 in Q4 2025.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $8873.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8873.0 (changed N/A YoY) and the FY2025 annual result came in at $4674.0, changed N/A from the prior year.
- Other Accumulated Expenses improved to $8873.0 in Q4 2025, from $4674.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $8873.0 in Q4 2025 to a low of $4674.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Regencell Bioscience Holdings | 2.61 Bn | 2.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8,873.00 |
| Jun 30, 2025 | 4,674.00 |